Dyspnoea in patients with chronic hepatitis C treated with pegylated interferon and ribavirin

By Garib Junia Rios   Garcia Guilherme Freire   Teixeira Rosâângela   Lima e Silva Francisco das Chagas  

Scandinavian Journal of Infectious Diseases, Vol. 43, Iss. 8, 2011-08 ,pp. : 625-631

Informa Healthcare

Access to resources Recommend Favorite

Monitoring Virological Responses to Interferon-Ribavirin and Interferon Monotherapy of Chronic Hepatitis C Re-treated due to Relapse or Non-response

By Westin Johan   Lindh Magnus   Nenonen Nancy   Lagging L. Martin   Norkrans Gunnar   Wejstal Rune  

Scandinavian Journal of Infectious Diseases, Vol. 33, Iss. 2, 2001-01 ,pp. : 110-115

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and Tolerability of Pegylated Interferon-α_2a plus Ribavirin versus Pegylated Interferon-α_2b plus Ribavirin in Treatment-Naive Chronic Hepatitis C Patients

By  

Intervirology, Vol. 53, Iss. 3, 2010-01 ,pp. : 146-153

Karger

Access to resources Recommend Favorite

Incidence of Depression in Patients with Chronic Hepatitis C Receiving Combination Therapy of Pegylated Interferon-Alpha and Ribavirin

By  

Psychotherapy and Psychosomatics, Vol. 83, Iss. 5, 2014-08 ,pp. : 308-309

Karger

Access to resources Recommend Favorite

Influence of Host and Viral Factors on Patients with Chronic Hepatitis C Virus Genotype 6 Treated with Pegylated Interferon and Ribavirin: A Systematic Review and Meta-Analysis

By  

Intervirology, Vol. 58, Iss. 6, 2016-03 ,pp. : 373-381

Karger

Access to resources Recommend Favorite